Royalty Pharma's Cliramitug Bet: A New Chapter in TTR Amyloidosis
Q2 2026 results show 14% royalty growth, a second guidance raise, and a $425M bet on a first-in-class amyloid depleter.
RPRX · Earnings Call · 2026-08-05
What Changed This Quarter
Royalty Pharma entered the second half of 2026 with unmistakable momentum. The company delivered 14% growth in royalty receipts, drove portfolio receipts 6% ahead of guidance, and for the second consecutive quarter “increased its full‑year guidance” — Pablo Legorreta, CEO · 2026-08-05 — now expecting $3.4–3.5 billion in portfolio receipts. But the headline event was the acquisition of a 3.75% royalty on AstraZeneca's Cliramitug for up to $425 million. This development‑stage asset is not merely another royalty; it is a first‑in‑class TTR fibril depleting antibody designed to remove amyloid deposits in the heart, differentiating it from the current standard of care.
"It would be impossible for me to replicate Royalty Pharma the way it is today." – Pablo Legorreta
This defensive yet forward‑looking deal deepens the company's TTR amyloidosis franchise, adding to its 2025 investment in Amvuttra. With the addition of cliramitug, Royalty Pharma now holds two differentiated approaches within the same therapeutic category, a strategy that has repeatedly validated its diligence model. The company's 90% success rate on development‑stage investments and the clinical rationale — strong biomarker data, a fully enrolled Phase III outcome trial, and blockbuster potential in a $7+ billion market — underpins confidence.
Portfolio Strength and the Moat
The quarter's financial performance reinforces the narrative of predictable, compounding growth. Total Revenue reached $631 million, up 11% year‑over‑year, while the FCF margin held at 94.6% (down 10.3pp from a peak, but still extraordinary). Management emphasized that “operating and professional costs equated to 4.8% of portfolio receipts” — Terrance Coyne, Executive · 2026-08-05 — evidence that the internalization transaction is delivering on its $100 million annual savings promise.
The company's scale and cost of capital remain the central entry barriers. Pablo Legorreta made this point explicitly during Q&A, noting that the portfolio is irreproducible — there is only one Tremfya royalty, one Trelegy royalty, and now one daraxonrasib royalty. This structural advantage is why synthetic royalty opportunity remains a growth pillar, with 2025 already marking a record year for such transactions. In the broader market context, the global trajectory shows disciplined commercial execution as a recurring theme, and Royalty Pharma's approach fits squarely within that pattern.
Cost Discipline and Balance Sheet Flexibility
Terry Coyne highlighted the financial flexibility now available: “following S&P's rating upgrade in June, Royalty Pharma is now BBB rated across all major credit rating agencies” — Terrance Coyne, Executive · 2026-08-05. That upgrade, combined with $812 million in cash, an undrawn $1.8 billion revolver, and $4 billion of total financial capacity, positions the company to capitalize on an expanding deal pipeline. The company returned ~$370 million to shareholders in the first half, including $100 million in buybacks, while staying disciplined about leverage (2.8x total debt to adjusted EBITDA, or 2.6x net).
This balance sheet strength is particularly relevant as the biopharma M&A environment heats up and R&D co‑funding conversations become more mainstream — a theme that was also prominent in the prior call, where Pablo noted "we're super excited about the opportunities — the universe of opportunities is clearly expanding." The company is not only the incumbent but also the natural partner for large pharma seeking to fund late‑stage programs without dilution.
Long‑Term Drivers and the Road Ahead
Looking toward 2030, Royalty Pharma reaffirmed its target of $4.7 billion or more in portfolio receipts. With the development‑stage pipeline now at 19 assets and peak royalty potential of approximately $2 billion, the company is well positioned to achieve this. The next major catalysts include the pelacarsen outcomes trial (expected in 2026), litifilimab Phase III data, and daraxonrasib in lung cancer (2027). Each could add meaningful royalty streams.
Beyond the product pipeline, the China opportunity remains a longer‑term growth vector. Management acknowledged it is still early days but is actively building local presence and monitoring out‑licensing transactions. The recent addition of a senior academic royalty leader (Greg Raskin) further expands the platform. As Pablo concluded, the company is "the undisputed leader in our industry," and this quarter's results — a second guidance raise, a high‑profile TTR deal, and consistent double‑digit growth — only reinforce that position.
In sum, Royalty Pharma's Q2 2026 was not a story of incremental improvement but of deliberate strategic expansion: deepening a high‑value therapeutic category, leveraging scale for a transformative acquisition, and demonstrating that its business model can thrive in any rate environment. The stock's +28% move over the past 90 days suggests the market is paying attention.